|
1
|
Kolev K and Longstaff C: Bleeding related
to disturbed fibrinolysis. Br J Haematol. 175:12–23. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Longstaff C and Kolev K: Basic mechanisms
and regulation of fibrinolysis. J Thromb Haemost. 13 (Suppl
1):S98–S105. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rijken DC and Lijnen HR: New insights into
the molecular mechanisms of the fibrinolytic system. J Thromb
Haemost. 7:4–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lin H, Xu L, Yu S, Hong W, Huang M and Xu
P: Therapeutics targeting the fibrinolytic system. Exp Mol Med.
52:367–379. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chapin JC and Hajjar KA: Fibrinolysis and
the control of blood coagulation. Blood Rev. 29:17–24. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Franchini M and Mannucci PM: Primary
hyperfibrinolysis: Facts and fancies. Thromb Res. 166:71–75. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rein-Smith CM and Church FC: Emerging
pathophysiological roles for fibrinolysis. Curr Opin Hematol.
21:438–444. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Leebeek FW and Rijken DC: The fibrinolytic
status in liver diseases. Semin Thromb Hemost. 41:474–480. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rabizadeh E, Cherny I, Lederfein D,
Sherman S, Binkovsky N, Rosenblat Y and Inbal A: The cell-membrane
prothrombinase, fibrinogen-like protein 2, promotes angiogenesis
and tumor development. Thromb Res. 136:118–124. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vanel D: The American college of radiology
(ACR) breast imaging and reporting data system (BI-RADS): A step
towards a universal radiological language? Eur J Radiol.
61:1832007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Plichta JK, Ren Y, Thomas SM, Greenup RA,
Fayanju OM, Rosenberger LH, Hyslop T and Hwang ES: Implications for
breast cancer restaging based on the 8th edition AJCC staging
manual. Ann Surg. 271:169–176. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
National Institutes of Health, National
Cancer Institute, U.S. Department of Health and Human Services, .
Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5×11.pdfPublished
November 27, 2017. June 20–2020
|
|
13
|
Pelosof LC and Gerber DE: Paraneoplastic
syndromes: An approach to diagnosis and treatment. Mayo Clin Proc.
85:838–854. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soomro Z, Youssef M, Yust-Katz S, Jalali
A, Patel AJ and Mandel J: Paraneoplastic syndromes in small cell
lung cancer. J Thorac Dis. 12:6253–6263. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Franchini M, Zaffanello M and Mannucci PM:
Bleeding disorders in primary fibrinolysis. Int J Mol Sci.
22:70272021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hunt BJ: Bleeding and coagulopathies in
critical care. N Engl J Med. 370:21532014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Naina HVK, Patnaik MM, Ali UA, Chen D and
Ashrani AA: Systemic fibrinolysis caused by tissue plasminogen
activator-producing metastatic breast cancer. J Clin Oncol.
28:e167–e168. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Winther-Larsen A, Sandfeld-Paulsen B and
Hvas AM: Hyperfibrinolysis in patients with solid malignant
neoplasms: A systematic review. Semin Thromb Hemost. 47:581–588.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kwaan HC and Lindholm PF: Fibrin and
fibrinolysis in cancer. Semin Thromb Hemost. 45:413–422. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cesarman-Maus G and Hajjar KA: Molecular
mechanisms of fibrinolysis. Br J Haematol. 129:307–321. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sacco E, Pinto F, Sasso F, Racioppi M,
Gulino G, Volpe A and Bassi P: Paraneoplastic syndromes in patients
with urological malignancies. Urol Int. 83:1–11. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Look MP, van Putten WL, Duffy MJ, Harbeck
N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M,
Eppenberger-Castori S, et al: Pooled analysis of prognostic impact
of urokinase-type plasminogen activator and its inhibitor PAI-1 in
8377 breast cancer patients. J Natl Cancer Inst. 94:116–128. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ruszkowska-Ciastek B, Kwiatkowska K,
Bielawska S, Robakowska M, Bielawski K and Rhone P: Evaluation of
the prognostic value of fibrinolytic elements in invasive breast
carcinoma patients. Neoplasma. 67:1146–1156. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wrzeszcz K, Słomka A, Zarychta E, Rhone P
and Ruszkowska-Ciastek B: Tissue plasminogen activator as a
possible indicator of breast cancer relapse: A preliminary,
prospective study. J Clin Med. 11:23982022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kulić A, Cvetković Z and Libek V: Primary
hyperfibrinolysis as the presenting sign of prostate cancer: A case
report. Vojnosanit Pregl. 73:877–880. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stephens RW, Brünner N, Jänicke F and
Schmitt M: The urokinase plasminogen activator system as a target
for prognostic studies in breast cancer. Breast Cancer Res Treat.
52:99–111. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Duffy MJ, McGowan PM, Harbeck N, Thomssen
C and Schmitt M: uPA and PAI-1 as biomarkers in breast cancer:
validated for clinical use in level-of-evidence-1 studies. Breast
Cancer Res. 16:4282014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Malmström P, Bendahl PO, Boiesen P,
Brünner N, Idvall I and Fernö M; South Sweden Breast Cancer Group,
: S-phase fraction and urokinase plasminogen activator are better
markers for distant recurrences than nottingham prognostic index
and histologic grade in a prospective study of premenopausal lymph
node-negative breast cancer. J Clin Oncol. 19:2010–2019. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Duffy MJ: The urokinase plasminogen
activator system: Role in malignancy. Curr Pharm Des. 10:39–49.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kyyriäinen J, Bolkvadze T, Koivisto H,
Lipponen A, Pérez LO, Ekolle Ndode-Ekane X, Tanila H and Pitkänen
A: Deficiency of urokinase-type plasminogen activator and its
receptor affects social behavior and increases seizure
susceptibility. Epilepsy Res. 151:67–74. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Resnati M, Pallavicini I, Wang JM,
Oppenheim J, Serhan CN, Romano M and Blasi F: The fibrinolytic
receptor for urokinase activates the G protein-coupled chemotactic
receptor FPRL1/LXA4R. Proc Natl Acad Sci USA. 99:1359–1364. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kortlever RM, Higgins PJ and Bernards R:
Plasminogen activator inhibitor-1 is a critical downstream target
of p53 in the induction of replicative senescence. Nat Cell Biol.
8:877–884. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kopp HG, Krauss K, Fehm T, Staebler A,
Zahm J, Vogel W, Kanz L and Mayer F: Symptomatic bone marrow
involvement in breast cancer-clinical presentation, treatment, and
prognosis: A single institution review of 22 cases. Anticancer Res.
31:4025–4030. 2011.PubMed/NCBI
|
|
34
|
Garufi G, Carbognin L, Orlandi A, Palazzo
A, Tortora G and Bria E: The therapeutic challenge of disseminated
bone marrow metastasis from HR-positive HER2-negative breast
cancer: Case report and review of the literature. Front Oncol.
11:6517232021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gradishar WJ, Anderson BO, Abraham J, Aft
R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD,
et al: Breast cancer, version 3.2020, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 18:452–478. 2020.
View Article : Google Scholar : PubMed/NCBI
|
